Discovery of a Potent and Orally Bioavailable Benzolactam-Derived Inhibitor of Polo-Like Kinase 1 (MLN0905)

Citations Over Time

Abstract

This article describes the discovery of a series of potent inhibitors of Polo-like kinase 1 (PLK1). Optimization of this benzolactam-derived chemical series produced an orally bioavailable inhibitor of PLK1 (12c, MLN0905). In vivo pharmacokinetic-pharmacodynamic experiments demonstrated prolonged mitotic arrest after oral administration of 12c to tumor bearing nude mice. A subsequent efficacy study in nude mice achieved tumor growth inhibition or regression in a human colon tumor (HT29) xenograft model.

Related Papers

• → Effect of retinol on iron bioavailability from Iranian bread in a Caco-2 cell culture model(2006)20 cited
• → Dissolution Systems for Chloramphenicol Tablet Bioavailability(1979)15 cited
• → Bioavailability of cyclandelate from capsules in beagle dogs and dissolution rate: Correlations with bioavailability in humans.(1991)5 cited
• → Study of the bioavailability of different formulations of 8‐methoxypsoralen in the dog(1988)4 cited
• → Prediction of Bioavailability(2003)2 cited